Saudi Arabia's HOR Company, with whom we have conducted business for approximately 20 years since 2005, won the Saudi Arabian government tender for the 2025 drug infusion rate controllers for public hospitals with the EZ Regular model. They have placed an order for the first batch: 225,000 units (equivalent to three 20-foot containers) and the existing contract quantity (equivalent to three containers). The challenge lies in producing and delivering within an extremely tight timeline, nearly impossible with the current workforce and systems while also manufacturing products already ordered from other countries. This marks the first time we've won and delivered for a public procurement tender. Public hospitals strictly enforce delivery schedules, and failure to meet them incurs significant penalties.

Saudi Arabia's HOR Company started its business with EZ Regular and has grown since. The Anyfusion cylinder pump, ACPi system, and Pro were introduced to numerous hospitals in 2023 through M Company, which is connected to the representative of this company. Following favorable reactions from users—nurses, pharmacists, and hospital officials—an exclusive supply agreement was established. The representative of M is a Saudi national with strong government connections. Users of the Anyfusion cylinder pump in domestic hospitals have completely overcome the issues of existing pumps. The severe leakage problems of previous pumps caused significant human error and an overwhelming workload, leading to high stress levels. These issues have been perfectly and cleanly resolved, resulting in happier users. We are confident that Saudi Arabian pharmaceutical infusion pump users will experience the same benefits as those in Korea and expect rapid expansion to public hospitals.

Saudi Arabia, driven by Crown Prince Mohammed bin Salman's innovative and challenging vision to reduce oil dependency, is strongly fostering manufacturing. It is being considered as a production base for supplying the Middle East region. The representative of Company M has proactively proposed joint investment through a leading, strategic cooperative relationship.

If the Anyfusion cylinder pump is listed and used at S University's two hospitals (main and branch campuses), Korea's top university hospital, and SS Hospital's main campus (currently undergoing a demo in the anesthesiology department), both of which are expected to purchase it after a demo this year, the major hospital supply track record and the ideal clinical results from major hospital users will be shared at various academic conferences. Furthermore, buyers and medical professionals from Saudi Arabia and other countries will visit these hospitals to observe Anyfusion in use. As global medical institutions adopt it, the paradigm of the drug infusion pump market will shift toward Anyfusion. This will establish Anyfusion, a pure domestic technology product, as the flagship product in medical institutions worldwide. It will become the first Korean company and product to lead and dominate a segment of the global medical market.

We extend our deepest gratitude to HOR's CEO and all employees for their utmost dedication in securing this government public procurement bid.

Thank you.